Get access to our best features
Get access to our best features
Published 8 months ago

New postpartum depression drug gets almost $16,000 price tag, raising questions about access

  • A newly approved medication to treat postpartum depression called Zurzuvae will be available in December at a cost of $15,900 per 14-day course, raising concerns about affordability and accessibility for patients.
  • Sage Therapeutics and Biogen, the drugmakers, aim to provide financial assistance and coverage plans to ensure broad and equitable access for women prescribed Zurzuvae. However, some experts worry that the high cost may exacerbate healthcare disparities, as therapy is often sufficient for treatment.
  • Postpartum depression, affecting 1 in 8 individuals who have babies, can have negative effects on maternal-infant bonding, family dynamics, and increase the risk of physical health issues. The approval of Zurzuvae offers an alternative to selective serotonin receptor inhibitors with potential faster improvements in depressive symptoms.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 93% of the sources are Center
93% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)